Background Across most of Australia, the role of community pharmacists in contraceptive care has been unchanged since 2004. To understand their current scope of practice and potential for practice advancements, we examined community pharmacists’ contraceptive knowledge and their attitudes, practices and perceived barriers to and benefits of contraceptive counselling provision.
Methods A nationwide postal survey was conducted between September and December 2020. We contacted a state/territory-stratified sample of 2149 community pharmacies and limited eligibility to one pharmacist per pharmacy. Summary statistics of respondent characteristics and parametric (χ2, linear regression) and non-parametric (Mann-Whitney, logistic regression) tests were computed for the outcomes: practices, knowledge (reported and tested), confidence, attitudes, barriers and benefits.
Results Eligible responses were received from 366 pharmacies (19%). Pharmacists’ median age was 34. Most (85% of) pharmacists agreed that contraceptive counselling fits within their current professional activities and emphasised benefits to their patients, including improved access to contraceptive decision support (80%), as being key motivators of counselling. A lack of payment mechanisms (66%), training opportunities (55%) and technical assistance tools (54%) were the most important barriers. Self-rated knowledge and confidence were highest for combined oral contraceptive pills and lowest for the copper intrauterine device (IUD). When tested, pharmacists were very knowledgeable about method, dosage, frequencies and costs, and relatively less knowledgeable about side-effects and IUD suitability for adolescents.
Conclusions Community pharmacists provide contraceptive information and counselling but lack the necessary resources and support to be able to consistently provide quality, person-centred care. Remuneration mechanisms, training opportunities and pharmacy-specific professional resources need to be explored.
- Health Services Research
- Contraceptive Agents, Female
- Pharmaceutical Services
- Patient Education as Topic
- Contraceptive Devices, Female
Data availability statement
Data are available upon reasonable request. De-identified data available for secondary analyses upon request.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @PipBuckingham, @wvnorman, @DrDebBateson
Contributors PB: conceptualisation (lead); methodology (lead); writing – original draft (lead). SH, JS, WVN, DB, DM: conceptualisation (supporting); methodology (supporting); writing – review and editing (equal); guarantor (DM).
Funding This work is supported by the National Health and Medical Research Council (NHMRC) grant number 1143492 (Centre for Research Excellence in Sexual and Reproductive Health for Women in Primary Care (SPHERE)), and the Australian Government Research Training Program. WVN holds the Canadian Institutes for Health Research-Public Health Agency of Canada Applied Public Health Chair in Family Planning Research CPP-329455-107837 2014-2024).
Competing interests DM has received research funding, travel grants and honorarium from Bayer. The other authors have no conflict of interest to declare.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.